April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
23 citations
,
March 2014 in “International Journal of Molecular Sciences” Testosterone reduces knee flexibility by affecting relaxin receptors.
The study investigated the effects of sex-steroids and menstrual cycle phases on knee ligament laxity in both rodents and humans. In rodents, ovariectomized rats treated with oestrogen and progesterone showed increased knee range of motion (ROM), while testosterone decreased it. This was linked to the up-regulation of relaxin receptor isoforms RXFP1 and RXFP2, which were antagonized by steroid hormone receptor blockers. In humans, female athletes and non-athletes exhibited significant differences in knee laxity across menstrual cycle phases, with the highest laxity during ovulatory and menstrual phases. Non-athletes had greater knee laxity compared to athletes. The study highlighted a strong correlation between knee laxity and serum relaxin levels, providing insights into the mechanisms of sex-steroid control of knee ROM and the increased susceptibility of females to non-traumatic knee injuries during certain reproductive phases.
29 citations
,
February 2018 in “Genetics research international” Certain genetic variations are linked to increased androgen levels in PCOS, but more research is needed to understand these connections fully.
14 citations
,
January 2018 in “Advances in Clinical Chemistry” The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.